FX.co ★ OmniScience And INmune Bio Unveil Partnership To Drive Faster Decision-Making In Alzheimer's Trial

OmniScience Inc. has announced a strategic partnership with INmune Bio Inc. (INMB), a biotechnology company currently at the clinical stage, aimed at enhancing INmune Bio's global Phase 2 Alzheimer's disease trial, AD02, through the use of OmniScience's innovative Vivo platform.

The AD02 trial is an international, blinded, randomized Phase 2 investigation of XPro in patients with Early Alzheimer’s Disease who exhibit biomarkers of elevated neuroinflammation. XPro is a cutting-edge inhibitor targeting tumor necrosis factor.

Vivo, powered by generative AI, serves as a clinical trial control tower, centralized to analyze clinical data in real-time. This platform delivers immediate insights, supporting rapid decision-making and optimizing trial outcomes.

This collaboration seeks to harness Vivo's advanced data analysis capabilities across various sources such as electronic data capture (EDC), clinical trial management systems (CTMS), and patient-reported outcomes (PROs) to streamline trial processes.

By swiftly integrating and analyzing large volumes of trial data, Vivo will empower INmune Bio's clinical teams to enhance data accuracy, identify any discrepancies, and expedite data-driven decision-making concerning patient enrollment and trial management.

INmune Bio has recently completed the randomization phase for its AD02 trial, including 208 patients diagnosed with early Alzheimer's and elevated neuroinflammation. The trial is now over-enrolled, with results anticipated in the second quarter of 2025.

Vivo is poised to play a pivotal role in accelerating cognitive result analyses, aiding clinical teams in delivering answers—and potentially treatments—to patients at an accelerated pace.

This partnership between OmniScience and INmune Bio highlights the transformative capabilities of generative AI in clinical trial management, improving efficiency and patient outcomes alike.

Both companies have integrated Vivo into INmune Bio's clinical development operations, with promising outcomes indicating improved collaboration and expedited decision-making.

OmniScience's CEO, Angela Holmes, has highlighted the partnership's promise, indicating that AI-driven insights through Vivo will further enhance clinical development capabilities.

At present, INMB's stock is valued at $5.19, marking an increase of 0.39%.